^
    Back
    Association details:
    Biomarker:BCR-ABL1 fusion
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:Tasigna (nilotinib) (Bcr-abl tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    REGIMENS FOR RELAPSED OR REFRACTORY Ph-POSITIVE B-ALL…Other Recommended Regimens...TKI (dasatinib, imatinib, ponatinib, nilotinib, or bosutinib)
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Chronic Myeloid Leukemia)
    New
    Excerpt:
    Tasigna is indicated for the treatment of:...adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase…